Hey Abobo, what will happen with a new delivery system for Relenza? Surely generics will have to develop their own delivery system and conduct trials and gain approval with regulators?
It's a pity that Biota couldn't get a settlement along the lines of Gilead which included higher royalty rates and active participation by Gilead in marketing.
The board has another shot with LANI, I just hope they are up to the task of negotiating with DS. Licensing the compound to DS for Japan only was okay since DS funded the trials. However for the ROW license striking a similar deal would be sub-optimal in my opinion. I'd prefer an internation partner with some serious power brokers pushing the compound to the US stockpilers.
us to buy more relenza, page-11
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)